WuXi NextCODE

101 Main Street, 14th Floor
Cambridge,  MA  02142

United States
Phone: 617-712-1417
http://www.wuxinextcode.com
  • Booth: 821


Powering Precision Medicine Worldwide

Profile

WuXi NextCODE offers uniquely comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine. These include a full range of sequencing services through our CLIA-certified laboratory; the world’s leading genome sequence analysis system; a novel database architecture that makes it possible to query, manage, store and share massive genomic data with unrivaled speed and efficiency; and the know-how and experience to apply genomics to optimize every aspect of drug discovery and development. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we enable clinicians and researchers at institutions and companies worldwide to use the full power of the genome to diagnose, treat and prevent disease.


 Press Releases

  • WuXi NextCODE and Fudan Children’s Hospital Partner to Lead Whole Genome Diagnostics for Rare Diseases in China

    Bringing the world’s leading genomics infrastructure into China’s top pediatric hospital will create national center of excellence for integrated diagnostics, research, treatment and care

    SHANGHAI; CAMBRIDGE, Mass.; and REYKJAVIK, 16 September 2015 – WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai and serving 2.3 million patients nationwide per year, today announced the signing of a landmark agreement for advancing precision medicine in China. It brings WuXi NextCODE’s renowned genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to begin immediately to deliver benefits to thousands of rare disease patients across China.

    WuXi NextCODE is deploying the full range of its renowned genome testing infrastructure for CHFU: CLIA sequencing, massively scalable informatics, and the most powerful interpretation tools and clinical genetics expertise. As a result, CHFU will be able to offer Chinese rare disease patients the same sequence-based diagnostics now available to patients in the United States and Europe through partners including Boston Children’s Hospital and Genomics England. CHFU, which sees as many as 7,000 patients every day, can now rapidly scale up sequence-based testing to resolve more undiagnosed cases.

    “We share a mission with CHFU: to put the best technology in the hands of the best doctors and scientists to help patients,” said Dr Ge Li, Chairman and CEO of WuXi AppTec, of which WuXi NextCODE is a wholly owned subsidiary. “We are very excited to join with our friends at CHFU to take the lead in rare disease diagnosis, care and research in China, offering patients world-class testing right here.”

    “Looking for the genomics infrastructure that could deliver the best results for our patients, we saw that our colleagues at Harvard Medical School and other leading institutions were choosing WuXi NextCODE,” said Guoying Huang, President of CHFU. “We’ve come to the same conclusion. Using the emerging global standard for genomic data in medicine, we can move beyond static gene panels to employ the full power of the genome to address rare diseases, genetic and genetics-related disorders and eventually cancer and other conditions as well. We can also collaborate instantly with sister institutions that use WuXi NextCODE’s system to push the frontiers of care and discovery.”

    “Our aim is to bring our technology into the clinic to deliver precision medicine to patients in every market worldwide,” said Hannes Smarason, co-founder, President and COO of WuXi NextCODE. “China is central to that strategy, and we couldn’t have a better partner than Fudan Children’s for realizing it and giving thousands of young patients and their families the best diagnostics and treatment options for inherited rare disorders.”

    WuXi NextCODE offers uniquely comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine. These include a full range of sequencing services through our CLIA-certified laboratory; the world’s leading genome interpretation system; a novel database architecture that makes it possible to query, manage, store and share massive genomic data with unrivalled speed and efficiency; and the know-how and experience to apply genomics to optimize every aspect of drug discovery and development. With offices in Shanghai; Cambridge, Massachusetts; and Reykjavik, Iceland, we enable clinicians and researchers at institutions and companies worldwide to use the full power of the genome to deliver precision medicine and support health. WuXi NextCODE is a wholly owned subsidiary of WuXi AppTec, the operating subsidiaries of WuXi PharmaTech (NYSE: WX). WuXi AppTec comprises a leading open- access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.

    Fudan University Children’s Hospital.
    Children’s Hospital of Fudan University is a prestigious tertiary academic medical center for children in China. Since its founding in 1952, it has been dedicated to providing pediatric patient care, education and research. CHFU is designated by the Ministry of Education as a key national center for pediatrics. It provides training programs for masters and doctoral degrees, as well as postdoctoral fellowships. CHFU has consistently led the field in China through the comprehensiveness of its capabilities. Its Institute for Pediatric Research has developed more than 100 tests for single-gene genetic diseases, established multidisciplinary teams of clinical experts, and is among the very first hospitals to adopt next generation sequencing. CHFU is a pioneer in the clinical diagnosis of genetic diseases in China.

    Contacts:

    WuXi NextCODE
    Edward Farmer
    VP Communications & New Ventures
    efarmer@wuxinextcode.com
    +1 781 775 6206

    WuXi AppTec
    Aaron Shi
    Director of Corporate Communications
    aaron_shi@wuxiapptec.com
    +86-21 5046-4362

    Children’s Hospital of Fudan University
    Liling Qian
    Director of Administrative Office, Institute for Pediatric Research Children’s Hospital of Fudan University

    ekyykyb@163.com
    +86-21 6493-1913 

  • Genomics England Contracts with WuXi NextCODE as Clinical Interpretation Partner in both Rare Disease and Cancer

    LONDON; SHANGHAI; CAMBRIDGE, Mass.; REYKJAVIK, 12 November 2015 – Genomics England has today announced that it has contracted with WuXi NextCODE as a Clinical Interpretation Partner for the 100,000 Genomes Project. The China, US and Iceland-based company is the first to work with them on cancer samples and will also interpret samples in rare disease. Genomics England will work with the clinical interpretation partners to drive up the quality of interpretation of genomic data. This will lead to better understanding of disease and more personalised care for patients in the future.

    The Project aims to sequence 100,000 whole genomes from approximately 70,000 people. Participants are NHS patients with a rare disease plus their families, and patients with cancer. The aim is to create a new genomic medicine service for the NHS, leading to more personalised care for patients. Some patients with rare disease may get a diagnosis for the first time, or discover what treatment might work best for them.

    WuXi NextCODE’s unique database model and clinical and tumor-normal analysis and reporting systems will enable NHS clinicians to begin to efficiently analyse patient sequence data and identify causative variants in rare diseases and driver mutations in tumors.

    Dr Augusto Rendon, Director of Bioinformatics at Genomics England said: “We are delighted to be working with WuXi NextCODE. Their sequence analysis platform will help us to return high quality variant interpretation results back to clinicians and make a direct impact on patient care.”

    Hannes Smarason, President and COO of WuXi NextCODE, a wholly owned subsidiary of WuXi AppTec (NYSE:WX), said: “We are very pleased to be playing a central role in a project that is a driving force for precision medicine worldwide. We look forward to putting our technology to work for NHS patients through interpretation and by applying the knowledge gained to advance the development of targeted new therapies for cancer and a range of rare conditions.”

    About Genomics England

    Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project. This flagship project will sequence 100,000 whole genomes from NHS patients and their families by 2017.

    Genomics England has four main aims:

    • to bring benefit to patients

    • to create an ethical and transparent programme based on consent

    • to enable new scientific discovery and medical insights

    • to kickstart the development of a UK genomics industry

      The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers.

      www.genomicsengland.co.uk

      About WuXi NextCODE
      WuXi NextCODE offers uniquely comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine. These include a full range of sequencing services through our CLIA-certified laboratory; the world’s leading genome sequence interpretation system; a novel database architecture that makes it possible to query, manage, store and share massive genomic data with unrivalled speed and efficiency; and the know-how and experience to apply genomics to optimize every aspect of drug discovery and development. With offices in Shanghai; Cambridge, Massachusetts; and Reykjavik, we enable clinicians and researchers at institutions and companies worldwide to use the full power of the genome to diagnose, treat and prevent disease. WuXi NextCODE is a wholly owned subsidiary of WuXi AppTec, the operating subsidiaries of WuXi PharmaTech (NYSE: WX). WuXi AppTec comprises a leading open- access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. 

  • Sidra Selects WuXi NextCODE to Power Population Genomics and Precision Medicine in Qatar

    In landmark partnership, Sidra Medical and Research Center, the genomics and informatics hub for the Qatar Genome Project, adopts the leading infrastructure for large-scale research and clinical genomics

    • Whole-genome pilot for 3000 samples using WuXi NextCODE system already underway

    • Data scientists from both organizations to collaborate on novel applications of WuXi

      NextCODE technology for clinical and research use at Sidra and for the QGP

    • Utilizing the same technology as leading genomics institutions in the US, Europe and China

      will accelerate benefits to patients in Qatar, the Arab world and globally

      DOHA; SHANGHAI; CAMBRIDGE, Mass.; and REYKJAVIK, 6 October 2015 – WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and Sidra Medical and Research Center (Sidra), a

      agreement to provide and co-develop comprehensive research and bioinformatics programs.

      “Understanding the genome is the key to building a roadmap for better health outcomes. We are really excited to be a part of a ground-breaking national project like the Qatar Genome Project as well as other research programs that will empower us and our partners to improve the health of the people in Qatar. Our work on the QGP has the potential to develop applications that will take our research and expertise beyond Qatar’s borders,” said Dr Francesco Marincola, Sidra’s Chief Research Officer. “The partnership with WuXi NextCODE brings us key capabilities: a fully integrated and truly scalable bioinformatics system for ramping up our sequencing effort, build a global standard database and tools using population genomic and medical data to benefit research and clinical care.”

      “Qatar is a small nation thinking big, committed to playing a leading role in making sequence data a standard part of healthcare,” said Hannes Smarason, co-founder, President and COO of WuXi NextCODE, a wholly owned subsidiary of WuXi AppTec (NYSE:WX). “Given our roots in Iceland and work with Genomics England and other large-scale projects, this collaboration is a natural fit for us. We are excited to be a part of it and to advance the practice of precision medicine with the stellar multinational team that Sidra has assembled.”

      Within a flexible multi-year framework, the partnership will enable Sidra to leverage its world- class clinical, research and bioinformatics teams to deliver cutting-edge genomic medicine – for its own patients as well as enhance its expertise to develop national, regional and global genomics research initiatives.

      The implementation will also allow Sidra to develop customized applications to support the genetic research needs of several health and research programs currently underway in Qatar, such as the Qatar Genome Project (QGP). QGP is a nationwide initiative launched by Her Highness Sheikha Moza bint Nasser at the World Innovation Summit for Health 2013. Its aim is to generate genome sequence and molecular ’omics data on the Qatari population and link it to a national electronic medical record (EMR) system that will help chart a road map for future advanced health care through personalized medicine.

      WuXi NextCODE’s technology was originally developed to conduct population research in Iceland – which is similar to the Qatar Genome Project in terms of sample size and participation.

    groundbreaking hospital, research and education

    institution, today announced a broad, long-term

    This system and its unique genomic database model - which manages and mines more sequences than any other system in the world – will streamline the flow of samples in and data out of Sidra’s high-throughput sequencing center. In addition to supporting the QGP, the implementation will facilitate clinical diagnostics and accelerate research priorities for the Genome Arabia Project, the genetics of type 2 diabetes as well as other research projects currently underway at Sidra.

    In partnership with Qatar Biobank, another key institution in the QGPs, Sidra is currently aiming to complete the pilot phase by May 2016. A whole-genome pilot of the Qatari population with a sample size of 3,000 - using the WuXi NextCODE system - is already underway. As the genomics and bioinformatics hub for the QGP, Sidra has set up a lab within Qatar Biobank with Laboratory Information Management Systems (LIMS); Quality Assurance (QA) and Quality Control (QC) metrics implementation and full speed data generation. Through innovation and integration of genomic technologies and health care, QGP will position Qatar as a global leader in personalized medicine and precision health.

    WuXi NextCODE offers uniquely comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine. These include a full range of sequencing services through our CLIA-certified laboratory; the world’s leading genome sequence analysis system; a novel database architecture that makes it possible to query, manage, store and share massive genomic data with unrivalled speed and efficiency; and the know-how and experience to apply genomics to optimize every aspect of drug discovery and development. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we enable clinicians and researchers at institutions and companies worldwide to use the full power of the genome to diagnose, treat and prevent disease. WuXi NextCODE is a wholly owned subsidiary of WuXi AppTec, the operating subsidiaries of WuXi PharmaTech (NYSE: WX). WuXi AppTec comprises a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.

    Sidra Medical and Research Center, based in Doha, Qatar, is a groundbreaking hospital, research and education institution, focusing on the health and wellbeing of women and children regionally and globally. Sidra will be a fully digital facility, incorporating the most advanced information technology applications in clinical, research and business functions. Sidra will initially have 400 beds with infrastructure to enable expansion to 550 beds in a subsequent phase.
    Sidra represents the vision of Her Highness Sheikha Moza bint Nasser, who serves as its Chairperson. The high-tech facility will not only provide world-class patient care but will also help build Qatar's scientific expertise and resources.
    Sidra is part of a dynamic research and education environment in Qatar that includes leading international institutions, such as Sidra’s academic partner Weill Cornell Medical College in Qatar. Through strong partnerships with leading institutions around the world, Sidra is creating an intellectual ecosystem to help advance scientific discovery through investment in medical research.
    Sidra will have a unique working structure with inter-professional collaboration at the heart, providing the best holistic care for patients and an unparalleled learning environment for its medical professionals. Sidra will combine the best in design, technology, operations and practices from medical centers around the world – to offer its employees an environment that is at once familiar and extraordinary.

    Contacts:

    WuXi NextCODE
    Edward Farmer
    VP Communications & New Ventures efarmer@wuxinextcode.com
    +1 781 775 6206

    Sidra Medical and Research Center

    Farhana Habib-Coelho

    Communications Specialist

    fcoelho@sidra.org

    +(974) 4404-2176 

  • Cancer, Meet the Alamo: San Antonio Enlists WuXi NextCODE to Speed Unparalleled Open-access Cancer Genome Project

    World’s leading genomics system to power the first longitudinal study of tumor-normal whole genome data matched in real time with patient progress and outcomes, freely available worldwide

    • The San Antonio 1000 Cancer Genome Project is collecting tumor and normal patient samples in the ten most common cancers from across a single metropolitan area

    • WuXi NextCODE’s CLIA laboratory will have sequenced the majority by year end.

    • The same WuXi NextCODE informatics driving big precision medicine efforts in the US, UK, Qatar and China will then catalogue the key differences between tumor and normal sequence

    • START is anonymously linking that data with treatment and outcomes data, creating a unique resource for directly applying genomics research to benefit patient care

      SAN ANTONIO; SHANGHAI; CAMBRIDGE, Mass.; REYKJAVIK; and MADRID, November 3, 2015 – The San Antonio 1000 Cancer Genomes Project (SA1kCGP), WuXi NextCODE, and South Texas Accelerated Research Therapeutics (START) today announced a partnership that will enable San Antonio’s pioneering city-wide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for this resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.

      START, which operates the world’s largest Phase I medical oncology program through clinical sites in the US, China and Spain, has contracted with WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, to sequence and interpret the samples. WuXi NextCODE will utilize its CLIA sequence laboratory and its HIPAA-compliant NextCLOUDTM secondary analysis and storage solution, powered by DNAnexus. START is connecting this “delta file” to anonymized patient electronic clinical records using the Medidata RaveTM system, and will make it available to qualified researchers and clinicians via the cloud.

      “We’re excited to announce the next phase in this pioneering effort, turning the talents and generosity of our community into better outcomes for patients,” said Aimee Locke, founder and president of SA1kCGP. “As global leaders in clinical development and genomics, and with operations in the US, Europe and China, our partners WuXi NextCODE and START are uniquely placed to help us deliver on this vision.”

      “Our three organizations share the mission of using our unique capabilities and assets to create better medicine for patients everywhere,” said Dr Anthony Tolcher, director of clinical research at START. “WuXi NextCODE was the logical partner in genomics. They bring to this project the same expertise they are deploying in large-scale precision oncology initiatives from Genomics England to Qatar, backed by the renowned clinical development capabilities of WuXi AppTec.”

      “San Antonio is innovating locally and impacting globally, an approach to precision medicine we are thrilled to be a part of,” said Hannes Smarason, co-founder, President and COO of WuXi NextCODE, a wholly owned subsidiary of WuXi AppTec (NYSE:WX). “This is a pathbreaking resource in scope, scale, and with START’s hallmark clinical rigor. We are all focused here on speeding the delivery of the latest in genome-driven therapy straight to cancer patients, wherever they may be.”

    About the San Antonio 1000 Cancer Genome Project. SA1kCGP is a pioneering cancer genome research project that has the unprecedented support of more than 200 surgeons, oncologists, and cancer researchers from a broad spectrum of affiliations. It is the largest community-wide undertaking of its kind and, most significantly, all data will be made available publicly at no cost to researchers worldwide. The project's promise to make all data freely available is built on the belief that no single investigator or institution has all of the answers and encourages the involvement of outsiders who might bring fresh ideas to the urgent and complex problem of gene abnormalities and cancer. The San Antonio 1000 Cancer Genome Project is a Texas not-for- profit 501 (c) (3) established to accelerate the development of a cure for cancer by conducting whole genome sequencing of cancerous and normal tissues. The project will link the genetic alterations that underlie the cancers to detailed clinical outcomes and all data will be made available publicly at no cost to researchers worldwide. www.sagenome.net.

    About START. With centers located in Madrid, Spain, Shanghai, China and San Antonio, Texas, START operates the largest, global, 24-hour Phase I research organization. START's mission is to accelerate the development of new anticancer drugs for the purpose of improving the quality of life and survival for patients with cancer. For information on START visit www.startthecure.com.

    WuXi NextCODE offers uniquely comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine. These include a full range of sequencing services through our CLIA-certified laboratory; the world’s leading genome sequence analysis system; a novel database architecture that makes it possible to query, manage, store and share massive genomic data with unrivalled speed and efficiency; and the know-how and experience to apply genomics to optimize every aspect of drug discovery and development. With offices in Shanghai, Cambridge, Massachusetts and Reykjavik, we enable clinicians and researchers at institutions and companies worldwide to use the full power of the genome to diagnose, treat and prevent disease. WuXi NextCODE is a wholly owned subsidiary of WuXi AppTec, the operating subsidiaries of WuXi PharmaTech (NYSE: WX). WuXi AppTec comprises a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.

    Contacts:

    WuXi NextCODE
    Edward Farmer
    VP Communications & New Ventures efarmer@wuxinextcode.com
    781 775 6206

    SA1kCGP & START
    Kelly Morris
    Kelly Morris Communications kellymorrispr@gmail.com
    210-930-5252 

Registration for ACMG 2017

Register will open in October 2016

March 21 - 25, 2017
Phoenix Convention Center
Phoenix, Arizona

Hotel Reservations

Reserve your room early to get the best choice.